Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.91
- Piotroski Score 3.00
- Grade Overweight
- Symbol (ZLAB)
- Company Zai Lab Limited
- Price $25.62
- Changes Percentage (-0.31%)
- Change -$0.08
- Day Low $25.16
- Day High $25.65
- Year High $36.60
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $75.50
- High Stock Price Target $101.00
- Low Stock Price Target $50.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.50
- Trailing P/E Ratio -5.71
- Forward P/E Ratio -5.71
- P/E Growth -5.71
- Net Income $-334,620,000
Income Statement
Quarterly
Annual
Latest News of ZLAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report
Zai Lab Limited (NASDAQ:ZLAB) shares dropped 13% to US$26.67 after its quarterly report. Analysts forecast a 64% revenue increase in 2025, with losses expected to decrease....
By Yahoo! Finance | 1 week ago -
Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability
VYVGART has shown steady growth with 1,000 new patients monthly, focusing on transitioning to maintenance settings. Expectations for the fourth quarter remain strong, potentially leading to significan...
By Yahoo! Finance | 1 week ago -
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo Finance
Zai Lab will showcase preclinical data of ZL-1503, a novel IL-13/IL-31 bispecific antibody for atopic dermatitis, at EADV Congress 2024. The presentation will cover the antibody's efficacy in treating...
By Yahoo! Finance | 1 month ago
